// App-Quantinova.ai

FR-OR37 : Nefecon® (Budesonide) Selectively Reduces Circulating Levels of BAFF (BLyS) and Soluble BCMA and TACI in IgA Nephropathy

Researchers

Presenter

  • Molyneux Karen

Principal Investigators

  • Barratt Jonathan

  • Wimbury DavidHarry John

Medical Centers

  • Mayer IgA Nephropathy Laboratory University of Leicester UK Leicester United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Nephrology

Disease

  • IgA nephropathy

Biomarkers

  • B-cell activating factor

  • Cluster of differentiation 79A

Drug/Treatment

  • Budesonide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved